World Heart Day 2022: How to better detect atrial cardiomyopathy to avoid atrial fibrillation?
On World Heart Day, Thursday, September 29, 2022, it is important to remember that the atrial fibrillation or atrial fibrillation (AF) is the most common heart rhythm disorder. In France, it is estimated that it affects 750,000 people and that it is responsible for nearly 20% of ischemic strokes (obstruction of the cervical artery).
To fight against this cardiac disorder, the ICAN UHI is developing MAESTRIA, an innovative project that aims to better detect atrial cardiomyopathy, responsible for the occurrence of atrial fibrillation and vascular embolic accidents, thanks to a consortium of 18 international partners. Discover this ambitious project below!
Atrial fibrillation, a growing heart disease
Heart rhythm disorders often cause a sensation of abnormal heartbeat (palpitation, irregular heartbeat…), but they can also be asymptomatic and diagnosed during a heart examination. They represent the 1st cause of sudden death before 35 years.
A rapidly growing heart disease, atrial fibrillation is a heart rhythm disorder strongly linked to the aging population. Up to 8% of people over the age of 80 suffer from it, and 110,000 to 230,000 new cases appear each year. The increase in its incidence and prevalence results in an estimated cost of care of approximately 2.5 billion euros per year in France.
It is therefore essential today to better understand this pathology, a real economic and public health issue.
The MAESTRIA project, in response to this public health issue
Launched in September 2021 and coordinated by Sorbonne University, the MAESTRIA (Machine Learning and Artificial Intelligence for Early Detection of Stroke and Atrial Fibrillation) research project has responded to the H2020 call for projects on digital diagnosis.
This international consortium brings together 18 partners from several European countries, the United States and Canada.
The objective of the project is to develop the 1rst digital platform for integrative diagnosis of atrial cardiomyopathy.
This tool will combine imaging data with physiological data (omics, clinical…) of patients, in order to obtain improved diagnostic accuracy through the identification of new therapeutic targets.
Its objective is to better prevent the complications of atrial cardiomyopathy (atrial fibrillation, strokes…) in order to increase the effectiveness and efficiency of treatments.
The project includes 3 strategic areas:
- Personalized diagnosis and innovative multidisciplinary care pathway, using genomic, metabolic and tissue inflammation research data,
- Risk stratification in AF patients with the use of artificial intelligence,
- Deployment of a digital diagnostic platform at the European level.
Who are the actors involved in this innovative project?
The 18 partners of the MAESTRIA consortium:
- Sorbonne Université (IHU ICAN)
- Assistance Publique des Hôpitaux de Paris (AP-HP)
- Oxford University
- Birmingham University
- AFNET
- Essen University
- Maastricht University
- National and Kapodistrian University of Athens
- CNIC
- Massachusetts General Hospital
- IMT Transfert
- Centre de Recherche du CHU de Sherbrooke
- Siemens Healthcare
- Caristo Diagnostics Limited
- Owkin
- Idoven
- Preventicus
- YourRhythmics